2912, 2021

Fibriant awarded Euro 16.5M EIC Accelerator funding to support RECOFIB development

December 29th, 2021|0 Comments

Leiden, The Netherlands, 23 December 2021 – Fibriant, a scale-up biotech company focused onthe development of the RECOFIB platform, was awarded up to € 16.5 million in funding of theEuropean Innovation Council Accelerator program Go [...]

512, 2019

Fibriant expands license adding recombinant human (pro)thrombin to existing recombinant fibrinogen capability – Company on track for clinical studies with RecoSeelTM in mild-to-moderate bleeding in 2021

December 5th, 2019|0 Comments

Leiden, The Netherlands, December 5, 2019 - Fibriant B.V., a developer of innovative recombinant fibrin(ogen) technology and products, today announced that it has expanded the existing recombinant fibrinogen license agreement with Bioceros B.V. for the [...]

301, 2019

Fibriant CEO Jaap Koopman to present at the 11th annual Biotech Showcase event 2019 on January 7 at 4.30 PM in the Hilton San Francisco Union Square in San Francisco, CA, USA.

January 3rd, 2019|0 Comments

Fibriant will provide an up-date on the progress with the development of their recombinant Fibrinogen technology platform and the product applications that are being evaluated.

506, 2018

Presentation by Prof. Matthew Flick at the 25th International Fibrinogen Research Society meeting in Winston-Salem, NC, USA.

June 5th, 2018|0 Comments

Prof. Flick, a leader in the field of Fibrinogen and host-defense, will present, also on behalf of Fibriant, new data generated in an ongoing collaboration with Fibriant. The lecture is entitled: A human fibrinogen variant [...]

501, 2017

Fibriant and Biomed Elements announce collaboration to develop a new topical hemostat product to stop severe bleeding supported by a MIT grant from the province of Zuid Holland, The Netherlands.

January 5th, 2017|0 Comments

Fibriant and Biomed Elements have entered into a research collaboration, combining their fibrinogen and biopolymer technologies, to develop a topical hemostat product for stopping severe life-threatening bleeding in the pre-hospital setting. Go to press release

2409, 2015

Fibriant Steps Up Development of Fibrinogen Technology Platform with License from TNO

September 24th, 2015|0 Comments

Exclusive License to Accelerate Development of New Breakthrough Products based on Specific Variants of Human Fibrinogen. Leiden, The Netherlands, September 24, 2015 - Fibriant B.V., a developer of innovative fibrinogen technology, today announced that it [...]